{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:50:51Z","timestamp":1792605051483,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives\/Background<\/jats:title><jats:p>This study was undertaken to compare the efficacy of the oral calcitonin gene\u2010related peptide receptor antagonist rimegepant relative to placebo as a preventive treatment for migraine in Japan. This was the first randomized placebo\u2010controlled trial of rimegepant for the preventive treatment of migraine to be conducted outside the United States and the second conducted globally.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this phase 3, double\u2010blind, randomized, multicenter trial, conducted August 9, 2022 through January 18, 2024, adults in Japan with a history of 4\u201318 migraine attacks\/month of moderate or severe pain intensity completed a 28\u2010day observation phase and then took rimegepant 75\u2009mg or placebo every other day during the 12\u2010week double\u2010blind treatment phase. The primary endpoint was the mean change from the observation phase in the number of monthly migraine days in the last 4\u2009weeks of the double\u2010blind treatment phase. Safety was assessed based on the frequency of adverse events and laboratory test abnormalities during the double\u2010blind treatment phase.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 484 (efficacy) and 496 (safety) treated participants were evaluable. During the observation phase, participants in the rimegepant and placebo groups, respectively, reported a mean (SD) of 9.3 (3.1) and 9.0 (3.1) monthly migraine days. The study met its primary endpoint with a statistically significant difference in mean change from the observation phase in the number of monthly migraine days in the last 4\u2009weeks of the double\u2010blind treatment phase (difference rimegepant vs. placebo: \u22121.1 [95% confidence interval = \u22121.73 to \u22120.38], <jats:italic>p<\/jats:italic>\u2009=\u20090.002). In the rimegepant and placebo groups, respectively, 54.7% and 41.0% of participants reported adverse events and 0.8% and 0.4% reported serious adverse events during the double\u2010blind treatment phase. No signal of drug\u2010induced liver injury due to rimegepant was identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Rimegepant 75\u2009mg every other day demonstrated efficacy superior to that of placebo for the preventive treatment of migraine, with a favorable safety profile. NCT05399485.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>This study tested the effectiveness of rimegepant for migraine prevention in Japan. Results showed that rimegepant was more effective than placebo in reducing monthly migraine days, with very few adverse effects. These results support the previous findings from a clinical study conducted in the United States and broaden them to a wider population.<\/jats:p><\/jats:sec><jats:sec><jats:label\/><jats:p>\n<jats:boxed-text content-type=\"graphic\" position=\"anchor\"><jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/head14995-fig-0002-m.png\"><jats:alt-text>image<\/jats:alt-text><\/jats:graphic><\/jats:boxed-text>\n<\/jats:p><\/jats:sec>","DOI":"10.1111\/head.14995","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T02:54:02Z","timestamp":1750474442000},"page":"1403-1412","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double\u2010blind, randomized controlled trial"],"prefix":"10.1111","volume":"65","author":[{"given":"Shigekazu","family":"Kitamura","sequence":"first","affiliation":[{"name":"Department of Neurology Konan Medical Center  Hyogo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[{"name":"Sendai Headache and Neurology Clinic  Miyagi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology Saitama Medical University  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-368X","authenticated-orcid":false,"given":"Tomofumi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yoshimatsu","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Thiry","sequence":"additional","affiliation":[{"name":"Pfizer  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D Japan  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Fullerton","sequence":"additional","affiliation":[{"name":"Pfizer  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Saitama International Headache Center Saitama Neuropsychiatric Institute  Saitama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[{"name":"Headache Center, Department of Neurology Tominaga Hospital  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00763-1"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1701015.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00569-3"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-021-00305-9"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01700-3"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00509-5"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01722-5"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12055"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_2_12_14_1","volume-title":"Clinical Practice Guideline for Headache Disorders 2021","author":"Headache Clinical Practice Guideline Development Committee","year":"2021"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S453806"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00126-6"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14994"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-024-00663-0"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.00030.x"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2001.01156.x"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.2307\/1912934"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/00031305.2000.10474549"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2008.01177.x"},{"key":"e_1_2_12_28_1","first-page":"258","volume-title":"Modern Epidemiology, 3rd Edition","author":"Greenland S","year":"2008"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2014.11.004"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-0133-1"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01481.x"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944"},{"key":"e_1_2_12_33_1","unstructured":"Pfizer.Nurtec ODT (rimegepant) orally disintegrating tablets prescribing information.2023. Accessed January 10 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212728Orig1s025Correctedlbl.pdf"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231219505"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00562-w"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:43:56Z","timestamp":1759729436000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/head.14995"],"URL":"https:\/\/doi.org\/10.1111\/head.14995","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"2025-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}